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Article 2:  
New insights into pathophysiology of dementia 
Abstract 
Improving understanding of brain disorders seems set to become one of the core 
applications of physiological research in the 21st century. Cognitive impairment and 
Dementia are not restricted to older people, but disorders that cause dementia tend 
to occur in later life so this article explores some of the emerging new insight to 
underlying pathophysiological processes. Although it is not yet clear whether 
dementia is the result of accelerated ageing of the brain or separate disease 
processes, new perspective can be applied to help to explain neurodegeneration in 
the most common forms of dementia.  Better understanding of these mechanisms 
can help nurses to consider their contribution to behaviours of those who are living 
with the disease.   
_________________________________ 
Dementia is an umbrella term for a chronic, progressive syndrome that is 
characterised by degeneration of the brain (World Health Organisation, 1992). This 
statement may be something of an oversimplification for challenges of Alzheimer’s 
disease, vascular dementia and neurodegenerative disorders that encompass 
difficulty in remembering, problems with learning new things, distorted awareness 
of the passage of time and a gradual loss of ability to make informed decisions (see 
article 1 of the series).  
Some 30 million people around the world live with dementia, which is equivalent to 
about 4.5% of people over 65 and up to 10% of those aged over 70. In the UK alone, 
the disease affects approximately 840,000 people – about 7% of people over 65 
years (Alzheimer’s Society UK, 2014) – with an estimated annual cost of £26 billion 
which is predicted to rise to over £50 billion in the next 30 years (Dept of Health, 
2015. Jenkins et al, 2016).  
Public awareness of dementia has grown because the disorder attracts more media 
headlines, so some people may become fearful that they are imagining symptoms if 
the normal age-related changes are poorly explained. Others may benefit from 
simple lifestyle-related advice that promotes successful ageing and may help to 
prevent dementia (see article 3 of this series). To be alive is to age, but some of the 
changes that occur in elderly people tend to be perceived as signs of deterioration 
and decline. Everyone who is involved with provision of care for those who have 
dementia bears a responsibility to ignore stereotypes of older people and see each 
person as a unique individual who has a particular set of talents, resources and 
challenges (see article 4 of this series).  
Dementia and neuro-inflammatory processes 
The apparently normal alterations in speed and memory that occur with advancing 
chronological age – “senior moments” - do not usually interfere with activities of 
daily living. Dementia is not a normal part of ageing but is a disabling condition that 
is characterized by progressive damage to neurons and their connections (see article 
1 of this series). Loss of volume in regions such as the hippocampus, basal ganglia, 
cerebellum and pre-frontal cortex of the brain can begin as early as the fourth 
decade (Selkoe, 2001; Linden, 2012). 
With a rapidly ageing population, it is imperative to identify modifiable risk and/or 
protective factors associated with cognitive decline and this is why mechanisms of 
brain inflammation (neuroinflammation) not caused by infective agents are 
attracting increasing interest.  They are – to an extent – atypical and different from 
acute or chronic inflammation that occurs elsewhere in the body, but are thought to 
accelerate loss of neurons and white matter within the brain (Trollor et al, 2012).  
Pathophysiology of excitotoxicity.  
It is clear that dementia is caused by an interplay between genes, lifestyle and 
environmental factors (Ferencz and Gerritsen, 2015) but until quite recently, it was 
generally assumed that death of neurons causes neurotransmitter loss, but 
alternatively neurotransmitter depletion itself may at least contribute to 
neurodegeneration. (Alisky, 2006) 
Regulation of extracellular concentrations of the neurotransmitter molecule 
glutamate (Figure 1) seems to be critical for normal brain function, processing speed 
and cognitive function because it contributes to long-term potentiation and plasticity 
amongst key neural structures important for memory and learning (Rudy et al, 
2015): -  
1. Glutamate molecules are packaged into synaptic vesicles before being 
released from neuron terminals on arrival of depolarizing action potentials.  
2. Glutamate binds to NMDA receptors and has an excitatory effect on post-
synaptic cells 
3. Glutamate is removed from the synapse by neighbouring astrocytes and/or 
the pre-synaptic neurons (Panatier et al, 2014) 
However, nervous tissue dies when too much glutamate is produced by pre-synaptic 
neurons, or when the ability of astrocytes to clear glutamate from the synaptic cleft 
is exceeded. Glutamate reaches pathological levels and promotes overstimulation of 
neurons through a process called excitotoxicity (see figure 2). Uncontrolled levels of 
glutamate may erode the integrity of vulnerable networks leading to progressive 
failure of complexly inter-connected neural networks (Stambler, 2015).  
Alzheimer’s disease (AD) 
The characteristic signs of this disorder are progressive loss of memory, declining 
executive function, difficulty with language and changes in behaviour caused by 
neurodegeneration that results from both genetic and environmental factors. AD 
affects almost 10% of adults over the age of 65 years and is a major cause of death.  
Alzheimer ’s disease is characterised by build-up of abnormal protein structures 
called “plaques” and “tangles” in many of the brain regions that are typically 
affected by the disease. The discovery of aggregation and deposition of amyloid-beta 
(Aβ) in the neuritic plaques and of hypophosphorylated tau protein in the 
intracellular neurofibrillary tangles led to the so-called amyloid hypothesis. The 
concept suggested that the abnormal form of amyloid-beta triggered a 
pathophysiological cascade that led to the disease.  
The time taken to develop these lesions is unknown; they probably evolve very 
gradually over a substantial period of time but it now seems likely that inflammatory 
processes and glutamate homeostasis are deregulated in Alzheimer’s disease. 
Inflammatory alterations in the permeability of endothelial tight junctions that 
create the Blood-Brain-barrier (BBB) further contribute to dysfunctional neuronal 
networks and, ultimately, to signs and symptoms of dementia (see Figure 3).  
The hippocampal circuits of the limbic brain – crucial for memory and learning - are 
amongst the earliest structures to be affected by degeneration so storage deficits 
are an important feature of the disease. Orientation to time and place are also 
disrupted early in the disease. People who have AD may find it difficult to prepare a 
meal or may ask a question several times – a result of rapid forgetting and poor 
recall of recent events and conversations. Nurses should expect to repeat what they 
say several times or allow more time to perform tasks (see article 3 of this series).  
There is widespread loss of acetylcholine and other neurotransmitters in Alzheimer’s 
disease and vascular dementia. Cholinergic neurons in the basal forebrain are lost at 
an early stage of Alzheimer’s disease but degeneration may be slowed through the 
use of cholinesterase inhibitors (see article 3) after a diagnosis of dementia has been 
confirmed.  
Figure 2: a feed-forward cascade of molecular and cellular events lead to the 
formation of amyloid plaques and neuritic tangles in the brain of people who are 
affected by Alzheimer’s disease (AD).   
 Vascular Dementia (VaD) 
Vascular dementia (multi-infarct dementia) is caused by impaired blood supply to 
the brain, possibly due to a series of microbleeds, transient ischaemic attacks (TIAs) 
or cerebrovascular incidents (strokes). Compared to AD, VaD is more often 
characterized by attention and concentration deficits, slowness of thoughts and 
word finding problems. However deficits that are experienced by the person depend 
on the location of cerebrovascular disease so it is a very heterogeneous disease  
Focal ischemia and oxygen-glucose deprivation disrupts metabolic processes in 
mitochondria of brain cells. Cells, including neurons, rely on homeostatic surveillance 
mechanisms and clearing of toxic intracellular components (Martinez-Vincente and 
Cuervo, 2007). In response to the hypoxic insult to brain tissue, white cells cross the 
blood-brain barrier to phagocytose debris  but the inflammatory response also 
increases production of reactive oxygen species (ROS) which further damages 
neurons (Witte et al, 2010) thus triggering the production of toxic levels of 
glutamate (see Figure 4). The subsequent pathophysiological cascade contributes to 
neuron losses and shrinkage of brain tissue (Sas et al, 2010) leading to signs and 
symptoms of VD.  
 
Deregulated lipid metabolism is emerging as an important risk factor for both stroke 
and vascular dementia. Human apolipoprotein E (apoE) is an important transporter 
of cholesterol in the CNS and loss of this function – especially through inheritance of 
the APOE4 allele – is another potential mechanism for degeneration (Rohn et al, 
2014) but which is tackled through the therapeutic use of statins (cholesterol-
lowering therapy).  
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Dementia with Lewy Bodies (DLB) or Parkinson’s disease dementia (PDD).  
Lewy bodies are microscopic, inclusion bodies in the cytoplasm of neurons, which 
are composed of abnormal forms of the proteins ubiquitin and α-synuclein. They 
form in regions throughout the brainstem, basal ganglia and cerebral cortex. The 
result is disruption to both cholinergic and dopaminergic pathways in the brain 
(Ballard et al, 2013; Gore et al, 2015).  
People who are affected experience visual disturbance and hallucinations, rapid eye 
movement sleep behaviour disorder (RBD), attention deficits and marked loss of 
neurons in the nigro-striatum. Changes in neurotransmitter systems also helps to 
explain the frequency of psychosis, depression and profound sensitivity to 
neuroleptic medications (which are dopamine antagonists) amongst the people who 
have this disorder.     
Frontotemporal dementia 
Frontotemporal dementia (FTD) refers to a diverse group of conditions that include 
Pick’s disease and which are sometimes misdiagnosed as mental health problems 
and/or associated with neurological problems. FTD can manifest as distinct subtypes: 
a behavioural subtype and a language disturbances subtype  
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About half of the people who are affected present with progressive aphasia 
(impaired language comprehension) while the remainder experience a distinct 
profile of symptoms including changes in personality and social behavior, loss of 
insight and empathy, neglect of responsibilities and diminished ability to self-care.  
 
Hyperphosphorylation of Tau leads to misfolding and formation of aggregates in 
FTD, but the significance of this protein pathophysiology is still unclear (Tenreiro, 
Eckermann and Outeiro, 2014)   
 
The average age of onset (52.8 years) of FTD means that the person who is affected, 
their families and loved ones have a distinctively different and more stressful 
experience compared with other forms of dementia (Bristow et al, 2008). The nature 
of the challenges means that carers often report that they feel less competent and 
have higher levels of distress requiring a great deal of support.  
The future of dementia care 
The population is ageing with increasing incidence of dementia so new strategies are 
needed to slow age-related decline in health and reduce disease-related cognitive 
impairment. Although the causes of dementia are not fully understood, it is clear 
that progress in molecular biology of neuroinflammation and excitotoxicity are 
advancing our knowledge of dementia beyond basic descriptions.  
The complex challenge of caring for those whose capacity is altered by cognitive 
impairment will be explored in articles 3 and 4 but it can help to have a sound grasp 
of the facts when having conversations with people who have dementia and their 
carers and families. The extent to which the mechanisms described here are involved 
in neurodegeneration is yet to be established but these processes may catalyse 
other on-going changes. In article 3, we explore a range of factors that increase the 
risk for dementia, but modifiable factors that have the potential to protect people 
from the onset of dementia are also of interest to all who are affected by dementia.  
Key Points.  
1. The population is ageing and prevalence of dementia doubles with every 5 
years so this article explains some of the pathophysiological processes that 
happen in the brain when dementia develops.   
2. The hallmark characteristics of normal ageing include low-grade 
inflammatory responses, alterations in metabolic processes, increasing frailty 
and reduced tolerance to physiological stressors - sometimes called 
“inflamm-aging” 
3. Promising insight to common pathways of disturbed homeostasis and the 
pathophysiology of dementia is emerging so existing models of dementia e.g. 
the amyloid cascade hypothesis, are reviewed to take account of new 
understanding of brain processes  
4. Improved understanding of neuroinflammation and neurotoxicity can help to 
explain the progressive nature of dementia and offer promising new 
approaches to elimination of aberrant homeostasis. 
5. Potential therapeutic strategies include inhibition of dyslipidaemias, 
management of insulin resistance, neutralisation of reactive oxygen species 
and increased levels of physical activity, which will be discussed in article 2 of 
this series.  
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